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Summary Experiments have been carried out both in vitro and in vivo to examine the possibility of
chemosensitization by misonidazole (MISO) at concentrations which are achievable in the clinic. Using
multicellular tumour spheroids in vitro we found that a 16h pre-incubation with 100pgml-1 MISO under
hypoxic conditions led to a considerable enhancement of sensitivity to melphalan (MEL) but not to CCNU.
Pre-incubation for 16h under hypoxia alone also produced a degree of sensitization to MEL, but there was
no effect of oxic pre-incubation with MISO. In vivo experiments using the KHT or RIF-l tumours in C3H
mice were designed so that repeated administration of MISO maintained blood concentrations of around
100 gml-l for either 7h or 16h. For the 7h regime, cytotoxic drugs were administered at the 4h point. In
most experiments the tumour response to MEL, cyclosphosphamide (CTX), chlorambucil or CCNU was no
greater in mice receiving multiple MISO than in mice receiving multiple injections of a balanced salt solution.
In the occasional experiment where there was an apparent increase in response, the effect was only small
(dose modifying factor <1.5). For the 16h regime the effect was studied of administering CTX (100mgkg-')
at various times during the regime. There was a clear trend towards increased CTX response in mice receiving
multiple MISO compared with controls. There was, however, no clear tendency for the effect to increase with
length of MISO pre-exposure.
The electron-affinic agent, misonidazole (MISO),
has been developed extensively as a radiation
sensitizer of hypoxic cells (Adams, 1977). More
recently, two separate lines of investigation have
suggested that this agent may be of clinical value in
producing selective sensitization of tumour cells to
some cytotoxic drugs. It was shown by Stratford et
al. (1980) that pre-incubation of Chinese hamster
ovary (CHO) cells with MISO under hypoxic (but
not oxic) conditions led to an enhanced sensitivity
to nitrogen mustard, melphalan and cis-platinum,
and this effect has been confirmed by Twentyman
(1982) using growth delay in EMT6 tumour
spheroids as the response endpoint. At the same
time, a number of in vivo studies (Rose et al., 1980,
Clement et al., 1980; Tannock, 1980; Law et al.,
1981; Twentyman, 1981; Martin etal., 1981; Siemann,
1981) have found that administration of MISO to
mice at or around the time of cytotoxic drug
administration can increase the anti-tumour effect
of the cytotoxic drug.
In some of these studies a therapeutic gain is
claimed in that the enhancement of the cytotoxic
drug effect against the tumour is greater than that
seen using a variety of normal tissue response
endpoints.
These experimental investigations, both in vitro
and in vivo, have, however, been carried out using
concentrations or doses of MISO which are much
higher than those normally attainable in the clinic.
The in vitro studies of Stratford et al. (1980) and
Twentyman (1982) both used a MISO
concentration of 5mM (1000ugml-1) and a pre-
incubation time of 2-5h. The various in vivo
experiments in the mouse have used MISO doses in
the range 1.5-5mMkg-' (0.3-1 gkg-'). These
would be expected to produce peak plasma
concentrations of 1.5-5mM (300-1000ugml-1). In
contrast the largest single dose of MISO which is
usually given in clinical practice (3gm-2) produces
peak plasma concentrations of only 0.5-0.75mM
(100-lSOugml-1) (for review see Workman, 1980).
The plasma half-life of MISO in humans, however,
is 10-20 times longer than in the mouse (Workman,
1980) and therefore the relative - contributions to
chemosensitization of peak plasma level and of
exposure time is clearly a matter of importance.
In this paper we describe experiments designed to
examine, both in vitro and in vivo the possibility of
chemosensitization by clinically achievable
concentrations of MISO. A study with similar
objectives, recently reported by Brown & Hirst
(1982) has produced encouraging in vivo data.
Materials and methods
Multicellular tumour spheroids
The growth conditions and experimental procedures
for in vitro experiments with spheroids of the
EMT6/Ca/VJAC mouse tumour line were as
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previously described (Twentyman, 1982). Briefly,
spheroids were grown in agar-coated flasks to a
diameter of 250,u and then transferred to 100ml-
spinner culture flasks for pre-incubation. In these
experiments, pre-incubation at 37°C was either in
the presence or absence of MISO (100 gml-') for
16h under either oxic or hypoxic conditions.
Hypoxia was achieved by passing nitrogen with 5%
CO2 (<lopt 10-6 02; British Oxygen Co.) into the
spinner vessels at a rate of 750-1000mlmin-'. After
pre-incubation and rinsing, spheroids were exposed
to graded concentrations of either melphalan (MEL)
or CCNU for 1h in glass tubes with intermittent
agitation. After this time, spheroids were again
rinsed and transferred to individual wells on 96-well
plastic multidishes. Successive measurements of
spheroid diameter were made and growth curves
constructed as previously described (Twentyman,
1982).
Mice and tumours
The mice used in these studies were inbred C3H/He
supplied by OLAC. Females were used in most
experiments, but males were used occasionally. Mice
entered experiments at age 12-16 weeks and
weighed 20-28 g.
Tumours used were the KHT and RIF-1
sarcomas, both of which originated in C3H/Km
mice at Stanford University, California, and which
have been previously described (Kallman et al.,
1967; Twentyman et al., 1980). The methods used
for tumour cell inoculation into the gastrocnemius
muscle of the hind limb and subsequent
measurement of tumour growth, including
conversion of leg measurement to tumour weight,
have also been described (Twentyman et al., 1979).
The endpoint of growth delay was calculated from
the time taken for individual tumours to reach 4 x
their initial treatment volume. Tumours were
treated in the size range 300-600mm3. Eight to 12
mice were used in each treatment group.
Drugs
Cytotoxic drugs for in vivo use were obtained,
prepared and administered as shown in Table I.
For in vitro use, MEL was dissolved in acidified
ethanol and CCNU in absolute ethanol so that a
volume of 0.03-0.2ml could then be added to 10ml
of medium to give the required final concentrations.
MISO for in vitro use was dissolved in Hanks'
balanced salt solution (HBSS) at a concentration of
2.5mgml-1 and then diluted 1:25 for pre-
incubation. For in vivo use, MISO was dissolved in
HBSS so that either the loading dose or "top-up"
doses could be administered in a volume of
0.01 ml g -. In order to achieve and maintain blood
MISO concentrations at or around 100pgml-', a
loading dose of 0.24mMkg-1 was given initially
followed by subsequent doses of 0.15mMkg-' at
30min intervals. These doses were based on data
from Brown (1982) and our own pharmacokinetic
data. All injections were via the i.p. route, and mice
not receiving MISO were given appropriate
volumes of HBSS as a control. Concentrations of
MISO and its metabolite desmethylmisonidazole
(DEMIS) in blood were monitored during all
Table I Cytotoxic drugs-Preparation and administration in vivo
Adninistration
Drug Supplier Preparation volume
cyclophosphamide Ward Dissolve in HBSS 0.005
(CTX) Blenkinsopp -0.02mlg-'
melphalan Chester Dissolve in acidified 0.01 mlg-'
(MEL) Beatty ethanol. Dilute 1:10
Research in propylene glycol-
Institute K2HPO4 buffer, final
pH 7.4
1-(2-chloroethyl)-3- U.S. Dissolve in absolute 0.005
cyclohexyl-1-nitrosourea National ethanol. Dilute 1:20 -0.015mlg-
(CCNU) Cancer in 0.5% carboxymethyl
Institute cellulose/Hanks
chlorambucil Chester (1) Dissolve in 0.01 mlg-
(CHL) Beatty absolute ethanol.
Research Dilute 1:10 in
Institute arachis oil B.P. or
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experiments using tail-vein sampling (Workman, 12+
1979) and reversed-phase high-performance liquid
chromatography analysis (HPLC) (Workman et al.,
1978). Studies were carried out to confirm that tail-
vein blood concentrations were identical to those 10
obtained after cardiac puncture.
Two regimes of multiple MISO administration
were used. In protocol A, administration continued
up to 7h, and the cytotoxic drugs were given 8
between the 3.5h and 4h injections. In protocol B A
0 (only used for CTX), multiple MISO administration c 0
was extended to 16h, and CTX was given either A A
immediately before the initial dose, or immediately co
before the 4, 8, 12 or 16h subsequent doses. Neither n 6
of these regimes resulted in a significant fall in g i
mouse body temperature. A A
CD ~~A A0
Results A *
A
In vitro A A
The results of spheroid growth delay experiments 2 A
are shown in Figures 1 and 2. In each case, any A
A
12+ _______________
o 0 2 4 6 8 10 12
/ 0 CCNU (jig ml-1)
10 / Figure 2 Growth delay in small (250p) EMT6
A spheroids induced by CCNU. Symbols as Figure 1.
growth delay due to pretreatment alone has been
I I subtracted before the points were calculated. Mean
8 A' * 2 // values for 5 experiments under each condition were
_ A, A ~~ ~~~A o / 0 A 0.0, 0.4 and 1.0 days for MISO alone, hypoxia alone
* / n / §// 0 and MISO plus hypoxia respectively. It may be
> / / @/ seen that for MEL (Figure 1), pretreatment with
=, 6 / MISO under hypoxic conditions leads to
o/ 0 considerable sensitization. There is also some
o / / A apparent effect of -pretreatment under hypoxia
AL/ / 06 ^/without MISO, but to a much smaller extent. Dose
4 6A / modification factors may be calculated from the
A* / a best lines fitted by eye to the points. For growth
* /Z<>? A delays of 5 days and 8 days respectively the values
/00 ,/ A are 1.27 and 1.61 for hypoxia alone and 2.76 and
2 A/ 0 2.87 for hypoxia+MISO. In contrast, the results for
CCNU (Figure 2) indicate little or no effect of
A*/'< 8 pretreatment under hypoxic conditions either with
A* or without MISO.
O 4 8 12 16 In vivo
Melphalan (pg mr-1) The blood concentrations of MISO obtained in the
Figure 1 Growth delay in small (250p) EMT6 2 experiments using the 16h protocol are shown in
spheroids induced by melphalan after various Figure 3. It may be seen that the regime was
conditions of pre-incubation for 16h. O oxic - successful in maintaining steady-state blood
MISO A oxic + MISO * hypoxic - MISO A concentrations close to the intended value of
hypoxic + MISO. 100ygml-'. Concentrations of the desmethyl190 P.R. TWENTYMAN & P. WORKMAN
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Figure 3 Plasma levels of MISO and the metabolite
DEMIS during the two 16h multiple-MISO injection
experiments. Open and closed symbols are 2 separate
experiments. Error bars represent +2 s.e. of the mean
for groups of4-5 mice.
metabolite DEMIS were also constant but at the
lower level of about 20 igml- . Steady state
concentrations of MISO and DEMIS obtained in
individual experiments using the 7h protocol are
summarised in Table II.
Results obtained for the response to cytotoxic
drugs injected 3.5-4h into the 7h protocol are
shown in Tables III-IV. For CTX (Table III) the
results are largely negative in that the growth delay
for a given CTX dose is not significantly different in
mice receiving MISO from that in mice receiving
HBSS. In one experiment (i.e. Expt. B, 100mgkg-1)
the difference is significant but the additional effect
in the MISO treated group is less than that
produced by increasing the CTX dose from 100 to
150mgkg-' in control mice. For MEL (Table IV),
the results are negative in 2/3 experiments. In
experiment B, however, enhancement of MEL by a
factor approaching 1.5 x was seen (i.e. MEL
Table II Steady-state blood concentrations of MISO
and its metabolite DEMIS in experiments using the 7h
protocol
Steady-state blood
concentration (pgml -1)
Experiment MISO DEMIS
A 83.8 (3.4) 19.3 (2.1)
B 93.4 (12.5) 21.2 (2.1)
C 95.4 (13.0) 29.2 (1.3)
D 91.8 (5.3) 18.9 (1.7)
F 108.5 (9.9) 15.8 (3.9)
G 113.3 (22.8) 24.1 (3.2)
H 113.0 (9.8) 31.1 (3.4)
Blood concentrations were normally measured at hourly
intervals from 1-7h, with 4-5 mice per group. The results
presented are the overall means of the individual group
mean values from 2-7h (n=6, except for Experiment G
where n=4) with 2 s.e. in parentheses.
Table III Growth delay in RIF-1 tumours treated with CTX
Time to 4 x treatment
volume (days)
CTX dose Multi HBSS Multi MISO
Experiment (mgkg-1) pretreatment pretreatment
A 0 3.7 (2.7- 5.1) 3.7 (2.8- 5.0)
100 11.9 (10.8-13.1) 13.2 (12.2-14.3)
B 0 7.2 (6.1- 8.5) 7.0 (6.2- 8.0)
100 16.1 (15.1-17.1) 20.8 (19.1-22.6)
150 23.6 (20.6-27.0)
C* 0 8.7 (7.7- 9.8) 8.0 (7.3- 8.8)
50 12.1 (10.8-13.6) 14.6 (13.7-15.5)
100 26.7 (22.0-32.2) 27.9 (22.4-34.7)
150 36.4 (32.7-40.7) 35.1 (30.3-40.7)
D 0 4.8 (4.2- 5.6) 5.1 (4.3- 6.0)
100 15.2 (14.6-15.8) 16.4 (15.1-17.8)
150 21.4 (19.1-24.1)
Values given are geometric means for groups of 8-12 mice. Figures
in parentheses are 2 s.e. limits.
*The control tumour growth rates and CTX growth delays are
atypically long in this experiment. In nearly all experiments with the
RIF-1 tumour, the time to 4 x treatment volume for control
tumours lies in the region 4-7 days.
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Table IV Growth delay in RIF-l tumours treated with melphalan
Time to 4 x treatment
volume (days)
MELdose Multi HBSS Multi MISO
Experiment (mgkg 1) pretreatment pretreatment
A 0 3.7 (2.7- 5.1) 3.7 (2.8- 5.0)
10 9.1 (7.8-10.6) 10.1 (9.0-11.2)
B 0 7.2 (6.1- 8.5) 7.0 (6.2- 8.0)
8 11.0 (9.8-12.5) 14.2 (13.0-15.5)
12 15.6 (14.5-16.9)
D 0 4.8 (4.2- 5.6) 5.1 (4.3- 6.0)
8 8.4 (7.1- 9.8) 8.8 (7.8-10.0)
12 11.7 (9.8-14.1)
Vales given are geometric means for groups of 8-12 mice.
Figures in parentheses are 2 s.e. limits.
Table V Growth delay in RIF-1 tumours treated with chlorambucil
Time to 4 x treatment
volume (days)
CHL dose Multi HBSS Multi MISO
Experiment (mgkg 1) pretreatment pretreatment
A 0 3.7 (2.7- 5.1) 3.7 (2.8- 5.0)
7.5 6.6 (5.7- 7.3) 7.3 (6.3- 8.6)
7.5 10.4 (9.6-11.3)*
D 0 4.8 (4.2- 5.6) 5.1 (4.3- 6.0)
10 9.0 (7.9-10.2) 12.7 (11.9-13.5)
15 11.9 (11.4-12.5)
F 0 6.2 (5.4- 7.2) 6.5 (5.5- 7.8)
8 8.5 (7.4- 9.6) 9.7 (8.8-10.6)
12 10.2 (8.8-11.8) 11.8 (10.7-13.1)
16 12.8 (11.2-14.6) 14.2 (13.1-15.3)
*Single dose MISO (2.5mMkg-') 30 min before CHL.
Values given are geometric means for groups of 8-12 mice.
Figures in parentheses are 2 s.e. limits.
8mgkg-1+MISO produces a growth delay nearly
equal to that given by MEL 12mgkg-1 alone).
The data for CHL (Table V) are again similar
with little or no enhancement being shown in 2/3
experiments. In experiment D, however, an
enhancement of slightly greater than 1.5 was
produced. It may be seen that in experiment A a
direct comparison was made of multi low-dose
MISO with the effect of a large single dose of
MISO given 30min before the CHL. The negative
result for the low dose protocol contrasts with the
clear enhancement produced by the single dose.
For CCNU (Table VI) neither experiment showed
a significant enhancement by multiple MISO.
In the light of these mainly negative results, 2
experiments were carried out with CTX in
combination with a 16h regime of MISO
administration. The results of the first experiment
are shown in Figure 4. It may be seen that at 2
times (i.e. 4 and 16h) the values for CTX with
MISO are significantly greater than those for CTX
with HBSS. At the other times, the values are also
greater but not significantly so. If all the groups are
combined (i.e. irrespective of relative time of
administration) the growth delay in mice receiving
HBSS+CTX was 11.0+2.2 days and that in mice
receiving MISO+CTX was 16.6 +2.3 days. In the
same experiment, we also looked at the effect of
large single doses of MISO, given 30min before
CTX (100mgkg-1) and obtained growth delays of
16.6+2.5 days for CTX+5mMkg-1 of MISO and
15.9±4.9 days for CTX+2.5mMkg-1MISO192 P.R. TWENTYMAN & P. WORKMAN
Table VI Growth delay in KHT tumours treated with CCNU
Time to 4 x treatment
volume (days)
CCNU dose Multi HBSS Multi MISO
Experiment (mgkg 1) pretreatment pretreatment
G 0 2.5 (2.3- 2.8) 2.8 (2.5- 3.3)
10 5.8 (4.1- 8.4) 7.4 (6.2- 8.8)
20 15.7 (11.0-22.0) 17.1 (13.8-21.0)
30 24.0 (21.0-28.0)
H 0 2.4 *(2.2- 2.7) 2.5 (2.2- 2.8)
10 5.1 (3.5- 7.4) 7.8 (5.1-11.7)
20 16.9 (15.4-18.5) 17.9 (17.3-18.6)
Values given are geometric means for groups of 8-12 mice.
Figures in parentheses are 2 s.e. limits.
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Figure 4 Growth delay in RIF-1 tumours induced by
CTX (100mgkg-1) injected at various times during
the 16h regime of multiple MISO or HBSS
administration. Error bars represent +2 s.e. of the
geometric mean for groups of 8-10 mice.
compared with 10.8 +2.0 days for CTX alone. It
would therefore appear that, in this experiment, the
multiple MISO regime produced as much
enhancement of CTX as a large single dose of
5mMkg- . An exact repeat of this experiment
produced the results shown in Table VII. It may be
seen that although the growth delays were shorter
in this experiment, the multiple MISO regime is
again about as effective as a large single dose MISO
(5mMkg- ') in enhancing the effect of CTX. It does
not appear, however, that either MISO regime is
capable of modifying the effect of CTX
(lOOmgkg-') to that produced by l50mgkg-' of
CTX alone.
Table VII Effect of CTX (lOOmgkg-1) on the RIF-1
tumour at various times during a 16h protocol of MISO
or HBSS administration
Time to 4 x treatment
volume (days)
Time Multiple Multiple
(h) HBSS MISO
0 15.5 (13.8-17.4) 18.8 (16.4-21.5)
4 18.0 (15.2-21.3) 17.1 (15.5-18.9)
8 12.6 (10.9-14.8) 16.4 (13.8-19.5)
12 13.5 (11.9-15.4) 17.4 (15.9-19.1)
16 15.8 (14.5-17.2) 17.3 (15.3-19.7)
All
times 14.9 (13.9-16.0) 17.4 (16.4-18.3)
combined
Control
i.e. 8.9 (8.1-9.6) 9.2 (8.1-10.6)
0 CTX
The growth delay is therefore 8.2 days for MISO pre-
treatment compared with 6.0 days for HBSS pretreatment.
In the same experiment, single dose MISO (5mMkg-1)
increased the growth delay due to CTX 100mgkg 1) from
6.0 days to 9.1 days, compared with 11.7 days for CTX
(150mgkg-1) alone.
Discussion
The data from our in vitro experiments indicate that
a 16-h exposure to 100gml-P1 of MISO under
hypoxic conditions makes spheroids much more
sensitive to growth delay induced by MEL. This is
not true, however, for CCNU. These results are in
agreement with our earlier study (Twentyman, 1982)
where there were also differences in the ability of
short hypoxic pre-exposure to MISO to sensitize
--j
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spheroids to these two agents. We found that dose
modifying factors were higher for MEL than for
CCNU, and that there was a greater tendency with
MEL than with CCNU for modification to depend
upon the length of the pre-exposure period.
The results for our in vivo experiments using a 7-
h MISO protocol are disappointing. In the majority
of experiments no significant increase in drug
response was caused by this MISO regime. Only in
a single determination for MEL and a single
determination for CHL are the data compatible
with a dose modification of around 1.5. The bulk of
the data suggest that dose modification by a factor
> 1.2 is unlikely. This is clearly less than the dose-
modifying factors which have been seen following
large single dose MISO in the RIF-1 tumour with
CTX (Twentyman, 1981; Law et al., 1981) or in the
KHT tumour with CCNU (Siemann, 1981;
Workman and Twentyman, 1982). The results are
contrary to those recently reported by Brown &
Hirst (1982) who used a similar 7-h MISO protocol
in the RIF-1 tumour and demonstrated clear
sensitization to MEL and to CTX. Also, using
different mouse tumour systems and 8h regimes of
MISO exposure, positive chemosensitization to
MEL and CTX has been found by Dr. N.J.
McNally (personal communication) but an absence
of effect is seen by Randhawa and Denekamp
(personal communication). This disparity of results
may indicate that the 7-8h exposures are close to
some critical level necessary for chemosensitization.
The 7-h regime with cytotoxic drug
administration at 3.5-4h was originally chosen by
Brown & Hirst (1982) as it closely resembles the
clinical situation as used in radiotherapy. The peak
plasma MISO concentration in man occurs at
around 4h after a single dose of 3gm2 and does
not fall much over the subsequent few hours. By
giving the cytotoxic drug at this time we therefore
had the advantage of a period of pre-exposure to
MISO before cytotoxic drug administration, high
levels at the time of drug administration, and
continuing high levels during the active life of the
drug. On the other hand, because of the relatively
rapid fall in MISO levels in the mouse following the
final MISO injection (t- 1 h compared with 10h
in man), the total area under the blood MISO
versus time curve (AUC) is still considerably less
for the 7h protocol in the mouse (3mM . h)
compared with that following 3gm2 in man
(8mM . h) (see Workman, 1980). We therefore
decided to extend the multiple injection regime in
the mouse to 16h (which does give an AUC of
-8mM h) in order to closely equate the total
MISO exposures.
Our data for CTX indicate that this 16h protocol
produces more enhancement than the 7h protocol.
However, there is a complete absence of time-
dependency in the effect, i.e. the time of CTX
administration with respect to the 16h MISO
regime does not appear to be critical. This is not the
result which would have been expected if the in vivo
effect were due solely to a progressive depletion of
thiols with time and may indicate that a number of
contributing mechanisms are involved as found in
vitro (Taylor et al.,1982).
In conclusion, therefore, our in vitro studies
indicate that clinically achievable MISO
concentrations cause considerable sensitization of
spheroids to MEL but not to CCNU. Our in vivo
results are mostly negative for a 7h MISO
protocol, but positive with CTX for a 16h regime.
We thank Jane Donaldson, Jill Shaw, Kate Smith, Nancy
Smith, Michael Walton and Karen Wright for their
excellent technical assistance.
References
ADAMS, G.E. (1977). Hypoxic cell radiosensitizers for
radiotherapy. In Cancer: A Comprehensive Treatise,
Vol. 6, (Ed. Becker) New York: Plenum Press, p. 181.
BROWN, J.M. (1982). Mechanisms of cytotoxicity and
chemosensitization by nitroimidazoles. Int. J. Radiat.
Oncol. Biol. Phys., 8, 675.
BROWN, J.M. & HIRST, D.G. (1982). Effect of clinical
levels of misonidazole on the response of tumour and
normal tissues in the mouse to alkylating agents. Br. J.
Cancer 45, 700.
CLEMENT, J.J., GORMAN, M.S., WODINSKY, I., CATANE,
R. & JOHNSON, R.K. (1980). Enhancement of
antitumour activity of alkylating agents by the
radiation sensitizer misonidazole. Cancer Res., 40,
4165.
KALLMAN, R.F., SILINI, G. & VAN PUTTEN, L.M. (1967).
Factors influencing the quantitative estimation of the
in vivo survival of cells from solid tumours. J. Natl.
Cancer Inst., 39, 539.
LAW, M.P., HIRST, D.B. & BROWN, J.M. (1981). The
enhancing effect of misonidazole on the response of
the RIF-1 tumour to cyclophosphamide. Br. J. Cancer,
44, 208.
MARTIN, W.M.C., McNALLY, N.J. & DERONDE, J. (1981).
The potentiation of cyclophosphamide cytotoxicity by
misonidazole. Br. J. Cancer, 43, 756.
ROSE, C.M., MILLAR, J.L., PEACOCK, J.H. & STEPHENS,
T.C. (1980). The effect of misonidazole on in vivo
tumour cell kill in Lewis lung carcinoma treated with
melphalan or cyclophosphamide. In Radiation
Sensitizers-Their Use in the Clinical Management of
Cancer. (Ed. Brady), New York: Masson, p. 250.194 P.R. TWENTYMAN & P. WORKMAN
SIEMANN, D.W. (1981). The in vivo combination of the
nitroimidazole misonidazole and the chemotherapeutic
agent CCNU. Br. J. Cancer, 43, 367.
STRATFORD, I.J., ADAMS, G.E., HORSMAN, M.R. & 4
others. (1980). The interaction of misonidazole with
radiation, chemotherapeutic agents or heat. A
preliminary report. Cancer Clin. Trials, 3, 231.
TAYLOR, Y.C., BUMP, E.A. & BROWN, J.M. (1982). Studies
on the mechanism of chemosensitization by
misonidazole in vitro. Int. J. Radiat. Oncol. Biol. Phys.,
8, 705.
TANNOCK, I.F. (1980). The in vivo interaction of anti-
cancer drugs with misonidazole or metronidazole:
cyclophosphamide and BCNU. Br. J. Cancer, 42, 871.
TWENTYMAN, P.R. (1981). Modification of tumour and
host response to cyclophosphamide by misonidazole
and WR 2721. Br. J. Cancer, 43, 745.
TWENTYMAN, P.R. (1982). Growth delay in small EMT6
spheroids induced by cytotoxic drugs and its
modification by misonidazole pretreatment under
hypoxic conditions. Br. J. Cancer, 45, 565.
TWENTYMAN, P.R., KALLMAN, R.F. & BROWN, J.M.
(1979). The effect of time between X-irradiation and
chemotherapy on the growth of three solid mouse
tumours: I. Adriamycin. Int. J. Radiat. Oncol. Biol.
Phys., 5, 1255.
TWENTYMAN, P.R., BROWN, J.M., GRAY, J.W., FRANKO,
A.J., SCOLES, M.A. & KALLMAN, R.F. (1980). A new
mouse tumour model system (RIF-1) for comparison
of end-point studies. J. Natl Cancer Inst., 64, 595.
WORKMAN, P., LITTLE, C.J., MARTEN, T.R. & 4 others.
(1978). Estimation of the hypoxic cell sensitizer
misonidazole and its 0-demethylated metabolite in
biological materials by reversed-phase liquid
chromatography. J. Chromatogr., 145, 507.
WORKMAN, P. & TWENTYMAN, P.R. (1982).
Enhancement by electron-affinic agents of the
therapeutic effects of cytotoxic agents against the
KHT tumour. Structure-activity relationships. Int. J.
Radiat. Oncol. Biol. Phys., 8, 623.
WORKMAN, P. (1979). Effects of pretreatment with
phenobarbitone and phenytoin on the
pharmacokinetics and toxicity of misonidazole in mice.
Br. J. Cancer, 40, 335.
WORKMAN, P. (1980). Pharmacokinetics of hypoxic cell
radiosensitizers. A review. In Radiation Sensitizers,
(Ed. Brady), New York: Masson, p. 192.